• Eltanexor Inhibits XPO1 to Suppress CRC via Wnt/β-catenin Mo

  2026-05-09

  The referenced study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, effectively reduces colorectal cancer tumorigenesis by suppressing Wnt/β-catenin signaling and lowering COX-2 expression. These findings highlight XPO1 inhibition as a promising chemopreventive strategy for high-risk colorectal cancer populations.

• Angiotensin III: Optimizing Cardiovascular & RAAS Workflows

  2026-05-08

  Angiotensin III (human, mouse) is redefining experimental precision in cardiovascular and neuroendocrine research, offering robust receptor signaling and superior solubility. Discover stepwise protocols, troubleshooting insights, and how recent findings elevate its value as a probe for both RAAS function and emerging infection models.

• Digoxin Beyond Cardiology: Precision in Cross-Domain Researc

  2026-05-08

  Explore digoxin as a Na+/K+ ATPase pump inhibitor with rigorously detailed protocol guidance, practical limitations, and advanced insights bridging cardiovascular and antiviral research. Distinct from existing content, this article delivers nuanced analysis to support robust experimental design.

• Metformin Hydrochloride: Integrative Mechanisms in Metabolic

  2026-05-07

  Explore how Metformin Hydrochloride (Metformin HCl) advances glucose metabolism and ossification research via multifaceted signaling modulation. This article uniquely synthesizes pathway insights and practical assay guidance for metabolic and bone biology studies.

• Quinolone–Coumarin Hybrids Display Potent Anti-Toxoplasma Ac

  2026-05-07

  This study evaluates novel quinolone–coumarin hybrids, derived from fluoroquinolones and novobiocin, for their in vitro anti-parasitic effects against Toxoplasma gondii. The findings highlight several hybrids with high selectivity and efficacy, providing promising leads for safer, more effective anti-toxoplasmosis agents.

• Deoxynivalenol Triggers Liver Injury via Mitophagy and Nrf2

  2026-05-06

  This study elucidates how deoxynivalenol (DON), a prevalent food and feed mycotoxin, induces liver injury by overactivating PINK1/Parkin-mediated mitophagy and inhibiting the protective p62-Keap1-Nrf2 signaling axis. These insights refine the mechanistic understanding of DON hepatotoxicity and offer a molecular foundation for developing targeted experimental models and interventions.

• Tyrothricin Mechanisms in Bacterial and Fungal Membrane Disr

  2026-05-06

  Explore Tyrothricin as a peptide antibiotic mixture with unique antimicrobial mechanisms, focusing on its disruption of bacterial and fungal membranes. This article delivers a deeper scientific perspective and actionable protocol insights for researchers.

• Dextrose (D-glucose) in Tumor Immunometabolism: Precision To

  2026-05-05

  Explore the pivotal role of Dextrose (D-glucose) in advanced tumor immunometabolism research. This article delivers deep insights into assay design, metabolic adaptation, and the translational potential of high-purity D-glucose for next-generation cancer studies.

• Cisplatin in Cancer Research: Protocols, Innovations & Pitfa

  2026-05-05

  Leverage Cisplatin (CDDP) for robust apoptosis assays and advanced tumor growth inhibition studies, optimizing workflows with evidence-backed parameters. Discover how recent research on DNA repair modulation is reshaping assay design and resistance studies.

• Tolazoline as an α2-Adrenergic Receptor Antagonist: Applied

  2026-05-04

  Tolazoline empowers researchers to dissect α2-adrenergic receptor signaling and insulin secretion modulation in vitro. This article delivers actionable protocols, troubleshooting intelligence, and workflow optimizations, revealing how APExBIO’s Tolazoline stands out in airway smooth muscle and islet function research.

• Vernakalant Hydrochloride: Mechanistic Insights and Clinical

  2026-05-04

  Explore the nuanced mechanism and clinical efficacy of Vernakalant Hydrochloride in atrial fibrillation treatment. This article delivers a mechanistic, evidence-driven perspective distinct from lab protocol guides.

• Ibuprofen: Applied Protocols for Colon Cancer Cell Research

  2026-05-03

  Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) is redefining apoptosis induction and cell cycle arrest workflows in colon carcinoma studies. This article details robust, data-driven experimental setups, advanced troubleshooting, and protocol enhancements for leveraging Ibuprofen in oncology research.

• Diclofenac: Non-Selective COX Inhibitor in Organoid Research

  2026-05-02

  Diclofenac, a high-purity non-selective COX inhibitor from APExBIO, empowers reproducible inflammation and pain pathway assays in cutting-edge hiPSC-derived intestinal organoid models. Explore practical setup, workflow innovations, and troubleshooting strategies to maximize translational value in anti-inflammatory drug research.

• NAT10-Driven ac4C Modification Stabilizes OGA mRNA in Oocyte

  2026-05-01

  Lin et al. (2022) reveal that N-acetyltransferase 10 (NAT10) maintains OGA mRNA stability via ac4C modification, directly impacting oocyte maturation. This study provides mechanistic insight into the post-transcriptional regulation of oocyte development and highlights novel intersections between RNA epigenetics and protein O-GlcNAcylation.

• Applied mCherry mRNA: Robust Red Fluorescent Protein Express

  2026-05-01

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) transforms reporter gene assays by combining advanced nucleotide modifications with a Cap 1 structure for high-efficiency, low-immunogenic red fluorescence. This article details stepwise protocols, advanced use-cases, and troubleshooting strategies, situating the product as a benchmark for stable, reproducible fluorescent protein mRNA expression.

16345 records 1/1090 page Next 12345 下5页 Last page